Oncology

Following the departure of its R&D head, Immunocore streamlines leadership, betting on internal experts to drive its next wave of innovative therapies.

Quetzal Therapeutics’ oral capsule for a rare leukemia could replace grueling IVs. The FDA's Fast Track status signals a major shift for patients and investors.

With a Super Bowl ad, NFL icons like Rob Gronkowski and Novartis are demystifying prostate cancer screening to save lives. Relax, it's a blood test.

With new manufacturing deals, CS Diagnostics is set to enter the competitive global hygiene market, targeting infection control from hospitals to homes.

A new center in China is using a novel drug and special policies to offer hope against NUT carcinoma, a rare and deadly cancer affecting the young.

A new endowed $50,000 grant from a powerhouse partnership aims to accelerate cancer cures by supporting early-career scientists at a critical juncture.

A new partnership integrates whole-genome sequencing into a clinical trial for a novel cancer drug, promising to accelerate development and usher in a new era.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

A new collaboration with Multiply Labs aims to use advanced robotics to automate cell therapy production, potentially making these cures accessible to all.

Neurocrine Biosciences begins a Phase 2 trial for a new tardive dyskinesia drug, aiming to build on its market dominance and offer new hope for patients.

With fresh funding, Primmune is advancing its unique TLR7 agonist, designed for efficacy without severe side effects, into a pivotal melanoma trial in Australia.

Janux Therapeutics appoints Dr. William Go, a key leader behind YESCARTA®'s approval, as CMO to steer its novel immunotherapy pipeline through critical trials.

Following impressive Phase 2 results, Scancell's novel immunotherapy iSCIB1+ receives FDA clearance for a pivotal trial, offering new hope for patients.

A new partnership aims to accelerate a pipeline of innovative multi-functional fusion proteins, potentially reshaping treatment for cancer and autoimmune disease.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.

With promising results in tough-to-treat colorectal cancer, a strong cash runway, and key alliances, Adagene is poised for a pivotal year.

Ontario's new FAST program provides accelerated funding for two key cancer drugs, cutting patient wait times and setting a new standard for access in Canada.

London's Ellipses Pharma in-licenses a novel B7H3 antibody-drug conjugate from Innolake, aiming to outmaneuver competitors with a unique payload.

PAQ Therapeutics advances its pan-KRAS degrader into human trials, backed by a $77M funding round, offering new hope for notoriously tough cancers.

A new, self-administered RNA therapy for hereditary angioedema gains EU approval, promising fewer attacks and greater freedom for thousands of patients.